EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSAPLG00000010971
Gene Symbol: GUCY1A1
2 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSAPLG00000016270
Gene Symbol: GUCY1A2
2 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSAPLG00000011190
Gene Symbol: GUCY1B1
2 Cross references
211 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H1

Ensembl ID : ENSAPLG00000011710
Gene Symbol: HRH1
2 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H2

Ensembl ID : ENSAPLG00000000743
Gene Symbol: HRH2
2 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H3

Ensembl ID : ENSAPLG00000012513
Gene Symbol: HRH3
1 Cross references
118 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 1

Ensembl ID : ENSAPLG00000014752
Gene Symbol: HDAC1
2 Cross references
298 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 10

Ensembl ID : ENSAPLG00000003588
Gene Symbol: HDAC10
2 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 11

Ensembl ID : ENSAPLG00000012032
Gene Symbol: HDAC11
2 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 2

Ensembl ID : ENSAPLG00000006926
Gene Symbol: HDAC2
2 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 4

Ensembl ID : ENSAPLG00000004358
Gene Symbol: HDAC4
2 Cross references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 7

Ensembl ID : ENSAPLG00000007048
Gene Symbol: HDAC7
2 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).